1-8 of 8
Michael T. Chiarella
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot
Journal: Blood
Blood (2022) 140 (Supplement 1): 12066–12067.
https://doi.org/10.1182/blood-2022-158042
Published: 2022
Journal Articles

Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD MS, Paul C. Hendrie, MD PhD, Bruno C Medeiros, MD, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1346.
https://doi.org/10.1182/blood.V130.Suppl_1.1346.1346
Published: 2017
Journal Articles

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Jeffrey E. Lancet, MD, Antje Hoering, PhD, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Michael T. Chiarella, Arthur C. Louie, MD, Bruno C. Medeiros, MD
Journal: Blood
Blood (2016) 128 (22): 906.
https://doi.org/10.1182/blood.V128.22.906.906
Published: 2016
Journal Articles

Burden of Acute Myeloid Leukemia (AML) Among Older Newly-Diagnosed Patients

Naomi C. Sacks, PhD, Phil Cyr, MPH, Yanmei Liu, MS, Derek J. Miller, MBA, Michael T. Chiarella, Arthur C. Louie, MD
Journal: Blood
Blood (2016) 128 (22): 4780.
https://doi.org/10.1182/blood.V128.22.4780.4780
Published: 2016
Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Bruno C. Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Geoffrey L. Uy, MD
Journal: Blood
Blood (2016) 128 (22): 902.
https://doi.org/10.1182/blood.V128.22.902.902
Published: 2016
Journal Articles

CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3

Jeffrey E Lancet, MD, Phillip Cyr, MPH, Naomi Sacks, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 4507.
https://doi.org/10.1182/blood.V126.23.4507.4507
Published: 2015
Journal Articles

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Jeffrey E Lancet, MD, Jorge E Cortes, MD, Tibor Kovacsovics, MD, Donna E. Hogge, MD, PhD, FRCPC, Jonathan E. Kolitz, MD, Martin S Tallman, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Eric Feldman, MD
Journal: Blood
Blood (2012) 120 (21): 3626.
https://doi.org/10.1182/blood.V120.21.3626.3626
Published: 2012
Journal Articles

Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.

Jeffrey E Lancet, MD, Eric J. Feldman, MD, Jonathan E. Kolitz, MD, Martin S. Tallman, MD, Donna E. Hogge, MD, PhD, Rami S. Komrokji, MD, Michael T. Chiarella, Arthur C. Louie, MD
Journal: Blood
Blood (2009) 114 (22): 1033.
https://doi.org/10.1182/blood.V114.22.1033.1033
Published: 2009